House committee grills Emergent CEO Bob Kramer over J&J vaccine debacle, ill-timed stock sale

Josh Sullivan

With Maryland CDMO Emergent BioSolutions still holding formation as the FDA mulls over operations at its Bayview Baltimore plant, CEO Bob Kramer has been hammered …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

House committee grills Emergent CEO Bob Kramer over J&J vaccine debacle, ill-timed stock sale

Josh Sullivan

Sign up to read this article for free.

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

Where the money is: The top 100 venture investors in biotech

How AI can address ongoing challenges in the life sciences industry

House com­mit­tee grills Emer­gent CEO Bob Kramer over J&J vac­cine de­ba­cle, ill-timed stock sale

Josh Sullivan

Sign up to read this article for free.

FDA meet­ing to pick next win­ter's flu shot is can­celed, in omi­nous sign for US vac­cine pol­i­cy

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

Af­ter re­jec­tion, Re­gen­eron seeks ac­cel­er­at­ed ap­proval of bis­pe­cif­ic for on­ly one of two types of lym­phoma

As­traZeneca’s SERD hits pri­ma­ry end­point in late-stage tri­al, but first-line po­ten­tial re­mains un­cer­tain

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

House committee grills Emergent CEO Bob Kramer over J&J vaccine debacle, ill-timed stock sale

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

After rejection, Regeneron seeks accelerated approval of bispecific for only one of two types of lymphoma

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

Where the money is: The top 100 venture investors in biotech

How AI can address ongoing challenges in the life sciences industry